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Summary
To prevent bleeding, dosage reduction of the novel anticoagulant rivaroxaban is 
recommended in the Dosage and Administration section of the drug package insert for 
patients with renal impairment. However, the dosage reduction criteria are not always 
followed in actual clinical settings. We therefore investigated the validity of the 
recommended dosage reduction criteria for rivaroxaban in patients with renal 
impairment. Subjects were 18 inpatients with renal impairment who were treated with 
rivaroxaban between July 2012 and May 2014 at the Japanese Red Cross Medical 
Center. In this retrospective observational study, patients were divided into the proper 
dose group (13 patients) and improper dosage group (5 patients) based on their medical 
records, and trough prothrombin time (PT) was analyzed. In the improper dosage 
group compared with the proper dosage group, PT was 2.4 s longer (p=0.05) after 
administration of rivaroxaban and the difference in PTs measured before and after 
administration was 1.8 s longer (p=0.35). These results suggest that the administration 
of rivaroxaban tends to increase risk of bleeding in patients with renal impairment if 
the dosage reduction criteria are not followed.
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Summary（和文）
　新規抗凝固薬Rivaroxabanは、腎機能障害患者の出血リスク管理の観点から、医薬品添
付文書の用法用量においては腎機能障害患者に推奨減量基準を設定している。しかし、
実際の臨床では、その減量基準が守られていない症例も少なくない。そこで腎機能障害
患者におけるRivaroxabanの推奨減量基準（以下、減量基準）の妥当性について検討を行 
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った。調査は、日本赤十字社医療センターにおいて2012年７月～2014年５月の間に 
Rivaroxabanが投与された腎機能障害を持つ入院患者18名を対象に、診療録による後方視
的観察研究を実施した。減量基準に従った群（適正用量群）13名と、減量基準に従わな
かった群（非適正用量群）５名に分け、プロトロンビン時間トラフ値（PT）を比較した。
結果、非適正用量群の投与後のPTは、適正用量群のそれに比べ、2.4秒延長した（p=0.05）。
また、非適正用量群の投与前後のPTの差（⊿PT）は、適正用量群のそれに比べ、1.8秒
延長した（p=0.35）。以上の結果から、腎機能障害患者におけるRivaroxaban減量基準を守
らないとPTが延長する傾向にあり、その結果出血リスクが増大する可能性が示唆された。
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Introduction
Atrial fibrillation is the most common type of arrhythmia encountered in daily clinical 
practice, and its incidence increases with age. Because atrial fibrillation is known to 
increase the risk of cerebral infarction, early detection of atrial fibrillation and early 
initiation of anticoagulant therapy in high-risk patients are important1.
In Japan, four novel oral anticoagulants (NOAC)—dabigatran, rivaroxaban, apixaban, 
and edoxaban—are currently approved for the use in anticoagulant therapy, in addition 
to the conventional warfarin. The preventive effects of these NOACs on atrial 
fibrillation–associated thromboembolic events– are expected to be similar or even 
superior to those of warfarin. Because NOACs have fewer interactions with other drugs 
or food and a greater range of effective blood concentrations, they are widely expected 
to replace warfarin as highly convenient drug alternatives2-4.
In April 2012, rivaroxaban, a NOAC and a selective inhibitor of Factor Xa, was 
approved in Japan for the prevention of ischemic stroke and systemic embolism in 
patients with nonvalvular atrial fibrillation (NVAF). The characteristics of rivaroxaban 
include a once-daily (OD) single-tablet regimen and, unlike warfarin, no need for 
frequent monitoring of bleeding events due to its stable pharmacokinetic and 
pharmacodynamic properties. However, because of the potential association between 
rivaroxaban and a high risk of bleeding in patients with impaired renal function, as 
reported by previous clinical trials5, 6, the package insert for rivaroxaban recommends 
reduced dosages according to the severity of renal impairment. Furthermore, because 
of the high incidence of bleeding in patients with impaired renal function, it is important 
to perform a clotting test to monitor bleeding events in clinical settings. The simple 
prothrombin time (PT) test has been shown to be most appropriate for this purpose7.
The package insert of rivaroxaban recommends dosage reduction criteria for patients 
with renal impairment. However, these criteria have not yet been validated. Therefore, 
to investigate the validity of the dosage reduction criteria, we used PT as a clotting 
test to evaluate bleeding risk in patients with renal impairment in real-world clinical 
practice.
― 2 ―
昭薬大・紀要　49,  2015
Methods
1 ．Study population
Subjects were inpatients with renal impairment (creatine clearance [Ccr] <50ml/min) 
who had been diagnosed as having NVAF and administered rivaroxaban for the first 
time between July 2012–May 2014 at the Japanese Red Cross Medical Center, Tokyo, 
Japan.
2 ．Research instruments
Clinical records were examined in a retrospective observational manner to extract 
patient backgrounds (age, sex, weight, Ccr, and rivaroxaban dosage) and PT values. Ccr 
was calculated using the Cockcroft-Gault equation. The Coagpia PT-N reagent 
(international sensitivity index, approximately 1.0; Sekisui Medical Co., Ltd., Tokyo, 
Japan) was used to measure PT.
3 ．Statistical analysis
Patients were assigned to the proper or improper dosage groups depending on 
whether rivaroxaban was given in accordance with the dosage reduction criteria for 
patients with renal impairment (Table 1). The PT test was performed before the 
administration of rivaroxaban and immediately before the administration on the 
following day (the PT trough value), and the difference in PT values (hereinafter ΔPT) 
measured before and after rivaroxaban administration were calculated.
Instead of unstable peak PT values, which vary among individuals8, 9, stable trough 
PT values were used in this study. In addition, patients were stratified according to the 
severity of renal impairment (moderate impairment, Ccr 30–49 ml/min; severe 
impairment, Ccr 15–29 ml/min) to compare the ΔPT values between the proper and 
improper dosage groups.
IBM SPSS Statistics 20.0 software was used for statistical analysis. Mann-Whitney’s 
U-test was performed to compare data with significance set at p<0.05.
Table 1．Dosage reduction criteria for rivaroxaban  
in patients with renal impairment
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4 ．Ethical approval
This study was approved by the Ethics Committee of the Japanese Red Cross Medical 
Center (Approval No. H26-538) and by the Ethics Committee of Showa Pharmaceutical 
University (Approval No. H26-13). Because of the retrospective observational nature of 
the study, no individuals were harmed.
Results
1 ．Patient background
Table 2 presents the characteristics of all 18 patients enrolled in this study. Table 3 
presents the characteristics of patients by dosage group.
Table 2．Patient characteristics
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Table 3．Patient characteristics by dosage group
2 ．PT values after rivaroxaban administration and ΔPT values between before and 
after administration
Table 4 shows median post dose PT values of 13.8 and 16.2 s in the proper and 
improper dosage groups, respectively, with a difference of 2.4 s between the groups 
(p=0.05). Median ΔPT values were 0.9 and 2.7 s in the proper and improper dosage 
groups, respectively, with a difference of 1.8 s between the groups (p=0.35) (Fig. 1).
Table 4．PT values after rivaroxaban administration and bleeding
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Fig. 1．Difference in PT values (ΔPT values) before and after rivaroxaban administration
3 ．Side effects
No side effects such as upper gastrointestinal bleeding were observed in either group 
(Table 4).
4 ．Differences by disease severity in ΔPT values in patients with renal impairment
4-1．Post dose ΔPT values in patients with moderate renal impairment
A total of 12 patients had moderate renal impairment (Ccr, 30–49 ml/min), of whom 9 
and 3 belonged to the proper and improper dosage groups, respectively. The median 
ΔPT values were 0.9 and 1.7 s in the proper and improper dosage groups, respectively, 
with a difference of 0.8 s between the groups (p=0.92).
4-2．Post dose PT and ΔPT values in patients with severe renal impairment
A total of 6 patients had severe renal impairment (Ccr, 15–29 ml/min), of whom 4 and 
2 were in the proper and improper dosage groups, respectively. Median ΔPT values 
were 1.75 and 8.45 s in the proper and improper dosage groups, respectively, with a 
difference of 6.7 s between the groups (p=0.06).
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Discussion
The aim of this study was to investigate the validity of the recommended dosage 
reduction criteria for rivaroxaban in patients with renal impairment in real-world 
clinical practice. This observational study, in which an increase in PT values was used 
as an indicator of bleeding risk, provided useful insights into how inappropriate dosing 
of rivaroxaban affects patients with renal impairment.
Post dose PT values and ΔPT values before and after rivaroxaban administration 
tended to increase in the group of patients administered an improper dosage of 
rivaroxaban, compared with those in the group of patients administered the proper 
dosage of 10 mg rivaroxaban. In the previous study investigating the effect of 10 mg 
rivaroxaban in patients with renal impairment, the post dose PT value was 11.6 s9. 
Reagents used in PT measurement are known to affect PT values. However, because 
both the PT reagent used in the previous study (HemosIL® RecombiPlasTin 2G) and 
the one used in the present study (Coagpia® PT-N) have an international sensitivity 
index of 1.0, it is appropriate to compare the PT values of 11.6 s and 13.8 s obtained 
after the administration of 10 mg rivaroxaban in the previous and present studies, 
respectively. Furthermore, the post dose PT value was 16.2 s in patients with renal 
impairment in the improper dosage group. This result is consistent with the previous 
study’s finding of prolonged PT in patients with renal impairment after the 
administration of an inappropriate dosage of rivaroxaban. Together, the findings of 
these studies elucidate the validity of the criteria for rivaroxaban reduction. 
Furthermore, stratification analysis based on disease severity revealed a marked 
increase in PT values when rivaroxaban was administered at an improper dosage in 
patients with renal impairment, so we can conclude that the dosage reduction criteria 
are valid and should be followed in clinical practice.
This study has some limitations, including its small sample size, single-center design, 
and short follow-up observation. Further investigation is therefore needed in order to 
verify the present findings. However, this study was the first to investigate the validity 
of the dosage reduction criteria for rivaroxaban in patients with renal impairment, and 
will serve as basic data for the use of post dose PT values and ΔPT values before and 
after drug administration to evaluate rivaroxaban-induced bleeding risks in patients 
with renal impairment.
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